ZA200601770B - Combination therapy for glycaemic - Google Patents

Combination therapy for glycaemic Download PDF

Info

Publication number
ZA200601770B
ZA200601770B ZA200601770A ZA200601770A ZA200601770B ZA 200601770 B ZA200601770 B ZA 200601770B ZA 200601770 A ZA200601770 A ZA 200601770A ZA 200601770 A ZA200601770 A ZA 200601770A ZA 200601770 B ZA200601770 B ZA 200601770B
Authority
ZA
South Africa
Prior art keywords
composition
glutaminyl
substance
treatment
diabetes mellitus
Prior art date
Application number
ZA200601770A
Other languages
English (en)
Inventor
Demuth Hans-Ulrich
Hoffmann Matthias
Glund Konrad
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of ZA200601770B publication Critical patent/ZA200601770B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA200601770A 2003-09-02 2006-02-28 Combination therapy for glycaemic ZA200601770B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02

Publications (1)

Publication Number Publication Date
ZA200601770B true ZA200601770B (en) 2007-07-25

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200601770A ZA200601770B (en) 2003-09-02 2006-02-28 Combination therapy for glycaemic

Country Status (14)

Country Link
US (1) US20060287251A1 (enExample)
EP (1) EP1663200A2 (enExample)
JP (1) JP2007504213A (enExample)
KR (1) KR20060119927A (enExample)
CN (1) CN1845731A (enExample)
AU (1) AU2004267955A1 (enExample)
BR (1) BRPI0413204A (enExample)
CA (1) CA2536432A1 (enExample)
EA (1) EA200600356A1 (enExample)
IL (1) IL173844A0 (enExample)
MX (1) MXPA06002127A (enExample)
NO (1) NO20061085L (enExample)
WO (1) WO2005020983A2 (enExample)
ZA (1) ZA200601770B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
US20130053310A1 (en) * 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
JP6329487B2 (ja) * 2011-10-28 2018-05-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療プロトコル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
ES2487897T3 (es) * 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DK1480961T3 (da) * 2002-02-28 2007-05-07 Prosidion Ltd Glutaminylbaserede DPIV-inhibitorer
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)

Also Published As

Publication number Publication date
EA200600356A1 (ru) 2006-08-25
CN1845731A (zh) 2006-10-11
NO20061085L (no) 2006-05-31
IL173844A0 (en) 2006-07-05
WO2005020983A3 (en) 2005-07-28
KR20060119927A (ko) 2006-11-24
JP2007504213A (ja) 2007-03-01
CA2536432A1 (en) 2005-03-10
BRPI0413204A (pt) 2006-10-03
AU2004267955A1 (en) 2005-03-10
US20060287251A1 (en) 2006-12-21
WO2005020983A2 (en) 2005-03-10
MXPA06002127A (es) 2006-05-31
EP1663200A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
US7078397B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7935723B2 (en) Use of organic compounds
US7241756B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
Gallwitz Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
CA2622579C (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
ES2390231T3 (es) Agentes farmacéuticos concomitantes y su uso
WO2007149797A2 (en) Use of organic compounds
KR20090038908A (ko) 대사 장애의 조합 치료
US20090054512A1 (en) Use of organic compounds
US20050014732A1 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
JP2012092136A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
KR20120016051A (ko) 제약 조성물
CA2581298A1 (en) Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
ZA200601770B (en) Combination therapy for glycaemic
SK287823B6 (sk) Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof
Del Prato Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
McIntyre et al. Vildagliptin
Makkar et al. Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes Mellitus